Introduction
Phosphatidylinositol 3-kinase (PI3K)-AKT pathway plays a cardinal role in the transduction of extra-cellular and intra-cellular signals that regulate cell growth, proliferation, survival, migration, and angiogenesis (1) . Activation of PI3K recruits AKT, a serine/threonine kinase, to the plasma membrane, allowing its activation, which in turn phosphorylates various intracellular proteins, including the serine/threonine kinase mTOR (mammalian target of rapamycin). PTEN, on the other hand, negatively regulates PI3K by dephosphorylating PIP3. Activation of PI3K pathway is common in cancer and inhibitors against various components of this pathway are at various stages of preclinical and clinical development for cancer treatment (1) .
Basal-like breast cancer is the most common subtype of triple negative (negative for estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu gene amplification) breast cancer (TNBC) that is associated with an aggressive clinical behavior and for which effective targeted therapies are lacking. Interestingly activation of PI3K/AKT pathway has been associated with basal-like or TNBC. A significantly higher level of AKT phosphorylation by immunohistochemistry (IHC) has been observed in TNBC patient specimens compared with non-TNBC (2) . In a study of 292 patients with invasive breast cancer, PI3K pathway activation, assessed by IHC analysis of phosphorylated AKT (pAKT), was significantly associated with basal-like phenotype and breast cancer specific mortality (3) . Similarly the level of pAKT was found to be higher by using reverse phase protein array analysis in basal-like breast cancers (4) .
In the recent report of The Cancer Genome Atlas (TCGA), the highest PI3K pathway activity was associated with basal-like breast cancer by both gene expression and phosphoproteomic analysis (5) . The increased level of pAKT correlated with lower PTEN protein expression and DNA copy number (4, 5) , which is frequently observed in basal-like breast cancer (3, 4, 6) . It has been reported that inhibitors against PI3K and mTOR reduced the proliferation of basal-like breast cancer cells in cell culture studies (4) , supporting PI3K pathway as a therapeutic target in this subtype of breast cancer.
We have decided to start with an mTOR inhibitor as our agent of choice since mTOR is the major downstream target of the PI3K/AKT pathway and inhibitors against mTOR are among the first that entered in the clinic. However, a low response rate (9%) of mTOR inhibitors in the treatment of breast cancer was observed in clinical trials of unselected patient population (7) .
One potential mechanism of resistance is the AKT activation induced by mTOR inhibitors through a negative feedback loop (8, 9) . Therefore, we hypothesized that inhibition of AKT could potentiate the anti-tumor effect of mTOR inhibitors and the combined targeting of mTOR and AKT could be an effective approach in treating basal-like breast cancer. In this study, we tested MK-2206, which is an AKT inhibitor, and Ridaforolimus MK-8669, an mTOR inhibitor, either alone or in combination in two patient-derived xenograft models of basal-like breast cancer. 6 and synergistic effect has been observed when MK-2206 was combined with various chemotherapy agents and small molecular inhibitors including erlotinib and lapatinib (10, 11) .
MK-2206 is the first allosteric AKT inhibitor to enter clinical trials and has been well tolerated (12) . The safety and well tolerated toxicity profile of MK-2206 makes it a feasible partner to combine with other agents to enhance its anti-tumor effect in clinical trials. In the treatment of breast cancer, MK-2206 is being developed as either a single agent (NCT01240928, NCT01319539, NCT01277757), or in combination with hormonal therapy (NCT01344031), laptinib (NCT01245205, NCT01281163) or paclitaxel (NT01263145). Results of these trials are pending (http://clinicaltrial.gov).
MK-8669 (Ridaforolimus, deforolimus, AP23573) is a novel selective non-prodrug analogue of rapamycin (structure published in reference (13) ) that is undergoing clinical development for cancer therapy (14, 15) . It has demonstrated broad anti-tumor activity in preclinical models of a variety of cancer types (13, 16) cells/well in 6-well plate and cultured for 1 day, followed by the addition of each agent alone or in combination at various concentrations. Cells were harvested 24 hours later and lysed in a buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% Triton, 1 mM PMSF and Protease Inhibitor Cocktail (Sigma) for 20 min on ice. Western blot procedures were performed using the standard techniques as described previously (23). All animal studies were carried out using the appropriate NIH animal care and the animal study protocol was approved by the Animal Studies Committee of Washington University.
Antibodies
The primary antibodies for both Western blot and IHC were the same for PTEN (Cell Signaling 
Western Blot
Western blot was performed according to previously published procedures (23).
Immunohistochemistry (IHC)
IHC of interested markers were performed on five-micron tissue sections from paraffinembedded tumor as described previously using the EnVision™+ Single Reagents HRP-Rabbit analyses were implemented in R 2.14.1 and GraphPad Prism. All tests were two-sided and significance was claimed at the 5% level unless otherwise noted. 
Results

MK-2206 in combination with MK-8669 inhibited tumor growth of patient-derived xenograft models of basal-like breast cancer with increased PI3K pathway activation
We had previously established WU-BC3, WU-BC4 and WU-BC5 TNBC xenograft models by direct implantation of patient tumor specimens to the humanized mammary fat pad of immune deficient NOD/SCID mice using a revised methodology described by Kuperwasser et al. (23, 26) . All 3 models were confirmed to be of human origin based on human specific cytokeratin staining and share similar gene expression pattern with their respective human tumor counterpart (23). WU-BC4 and WU-BC5 were classified as basal-like by PAM50 (23, 27, 28). In vitro cultured WU-BC3 cell line which was derived from WU-BC3 xenograft was also basal-like, although the in vivo xenograft tumor of WU-BC3 was more similarly clustered to the HER2-E subtype, but without HER2 over expression (23). Western blot analysis of pAKT and pS6 indicated an activated PI3K pathway signaling in WU-BC4 and WU-BC5 but not WU-BC3 (Fig.   1a ). This is consistent with the loss of PTEN protein expression in tumor cells of WU-BC4 and WU-BC5 but not WU-BC3 (Fig. 1b) . Furthermore, PTEN gene deletion was detected in WU-BC5 but not in WU-BC3 by Comparative Genomic Hybridization (aCGH) (data not shown).
Loss of PTEN expression in WU-BC4 is likely epigenetic since PTEN is normal by both aCGH and genomic sequencing (data not shown). No somatic mutations were detected in other PI3K pathway genes including PIK3CA and AKT1 in these 3 models. These data suggest that the increased PI3K pathway activity in WU-BC4 and WU-BC5 is likely due to loss of PTEN expression. 
(p<0.001), respectively, in WU-BC4, and by 71% (p<0.001), 64% (p<0.001), and 88% (p<0.001), respectively, in WU-BC5 (Fig. 2a and 2b) . A synergistic effect on Ki67 was observed for combination therapy in both models by examining the interaction effect in the twoway ANOVA model (p=0.0051 in WU-BC4 and p=2.89e-08 in WU-BC5) (Supplemental Fig.   2 ). The degree of apoptosis induction as assessed by IHC of cleaved caspase 3 was small, less than 3%, consistent with a cytostatic rather than cytotoxic effect of this treatment in these models. MK-2206 had minimal effect on CD31 staining in WU-BC4, but led to 37% reduction in WU-BC5 (p<0.001). Combination therapy reduced CD31 staining by 54% in WU-BC4 (p<0.001) and 71% in WU-BC5 (p<0.001). There was no synergism observed between the 2 agents.
MK-
MK-2206 suppressed MK-8669-induced AKT activation
To investigate target inhibition by MK-2206 and MK-8669, WU-BC4 treated with either vehicle, MK-2206, MK-8669, or the combination of MK-2206 and MK-8669, were analyzed for the levels of pAKT and pS6 (Fig. 3) . MK-2206 reduced the level of pAKT and, to a lesser degree, addition of MK-2206 abolished the pAKT expression, which provides a potential mechanism for the additive or synergistic effect observed for these two agents.
PTEN knockdown sensitizes the growth inhibitory effect of mTOR and AKT inhibition
PTEN loss is the most common cause of PI3K pathway activation in basal-like breast cancer. To evaluate the effect of PTEN status on tumor cell sensitivity to PI3K pathway inhibition, we generated stable knockdown of PTEN in the cell line derived from the WU-BC3 patient-derived xenograft model. As shown in Fig. 4 , PTEN knockdown in WU-BC3 (shPTEN) led to an increase in the level of pAKT and pS6, indicating activated PI3K pathway signaling compared to control knockdown in WU-BC3 (shGFP). In cell culture experiments, treatment with MK-2206 led to a dose dependent reduction in the levels of pAKT, and to a lesser degree the levels of pS6 and p4EBP1 (Fig. 4a) . Treatment with MK-8669 led to a concentration dependent reduction in the level of pS6, but also an increase in pAKT at lower dose levels, consistent with the feedback upregulation of AKT activity following mTOR inhibition. The increase in pAKT level was effectively abolished by co-administration of increasing concentrations of MK-2206 (Fig. 4a) .
We then compared the effect of MK-8669 and MK-2206 on cell proliferation in WU-BC3 (shPTEN) and WU-BC3 (shGFP) (Figs. 4b, c, d , and Table 1 ). The IC50 for both agents alone was lower in WU-BC3 (shPTEN) than that in WU-BC3 (shGFP), indicating a greater sensitivity to both agents with the loss of PTEN. A strong synergistic effect of these two agents on cell proliferation was observed in WU-BC3 (shPTEN), not in WU-BC3 (shGFP) ( Table 1) (Fig. 5a) and a higher baseline level of pAKT compared to WU-BC3 (shGFP) (Fig. 5b) . Treatment with MK-8669 induced a higher pAKT level which was abolished by the addition of MK-2206 in both models (Fig. 5b) .
In WU-BC3 (shGFP), only combination therapy induced significant tumor growth inhibition (21%; p<0.001) (Fig. 5c) . In contrast, MK-8669 and the combination induced significant tumor 
literature report the mTOR inhibition decreased expression of hypoxia inducible factor-1 (HIF-1), an important stimulator of vasculogenesis (37) .
An advantage of our study is the use of early passage patient-derived xenograft models, which are more closely related to the human tumor counterpart. These xenograft models preserve cell morphology, architecture and molecular features and recapitulate the biology of their human counterpart (23, 38-41). Importantly, drug response of a tumor xenograft and its original human counterpart has been found to be highly correlated (38, 39 The Combination Index (CI) value was calculated for ED50, ED75, and ED90; the average CI value for each combination is also shown. A CI of <0.3 indicates a strong synergistic effect, 0.3< CI < 0.7 a synergistic effect, 0.7 < CI < 0.9 moderate synergy, 0.9 < CI < 1 additive effect, and CI > 1 antagonistic effect.
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